12/14
07:30 am
pgen
Precigen, Inc. (NASDAQ:PGEN) is definitely on the radar of institutional investors who own 31% of the company [Yahoo! Finance]
Low
Report
Precigen, Inc. (NASDAQ:PGEN) is definitely on the radar of institutional investors who own 31% of the company [Yahoo! Finance]
11/25
06:53 am
pgen
Precigen Is Still A Buy After The Papzimeos Rally [Seeking Alpha]
Low
Report
Precigen Is Still A Buy After The Papzimeos Rally [Seeking Alpha]
11/14
02:07 pm
pgen
Vaxart, Precigen among biotech gainers after Q3 results [Seeking Alpha]
Low
Report
Vaxart, Precigen among biotech gainers after Q3 results [Seeking Alpha]
11/14
08:09 am
pgen
Precigen (NASDAQ:PGEN) had its price target raised by analysts at HC Wainwright from $8.50 to $9.00. They now have a "buy" rating on the stock.
High
Report
Precigen (NASDAQ:PGEN) had its price target raised by analysts at HC Wainwright from $8.50 to $9.00. They now have a "buy" rating on the stock.
11/14
12:10 am
pgen
Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... [Yahoo! Finance]
High
Report
Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... [Yahoo! Finance]
11/6
05:06 pm
pgen
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 [Yahoo! Finance]
Low
Report
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 [Yahoo! Finance]
11/6
04:30 pm
pgen
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
Low
Report
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
10/16
05:39 pm
pgen
Patient Opportunity Equity Strategy Q3 2025 Portfolio Recap [Seeking Alpha]
High
Report
Patient Opportunity Equity Strategy Q3 2025 Portfolio Recap [Seeking Alpha]
10/13
07:34 am
pgen
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis [Yahoo! Finance]
Low
Report
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis [Yahoo! Finance]
10/13
07:00 am
pgen
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
Low
Report
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis